NeuroBo Pharmaceuticals, Inc. (NRBO)
Stock Price:
$6.30 USD
-0.11 (-1.72%)
Updated Aug 3, 2020 1:21 PM EDT - Market open
Key Info
| Market Cap |
103.49M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-22.24M |
| Shares Out |
16.43M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$6.30 |
| Previous Close |
$6.41 |
| Change ($) |
-0.11 |
| Change (%) |
-1.72% |
| Day's Open |
6.44 |
| Day's Range |
6.30 - 6.66 |
| Day's Volume |
19,899 |
| 52-Week Range |
6.02 - 30.00 |
More Stats
| Market Cap |
103.49M |
| Enterprise Value |
93.79M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.43M |
| Float |
2.48M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.53 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
200,805 |
| Short Ratio |
2.76 |
| Short % of Float |
6.87% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
13.92 |
| Revenue |
n/a |
| Operating Income |
-22.71M |
| Net Income |
-22.24M |
| Free Cash Flow |
-8.22M |
| Net Cash |
9.70M |
| Net Cash / Share |
0.59 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-35.62% |
| ROE |
-421.04% |
| ROIC |
1,170.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
20.0
Current: $6.30
High
20.0
Target: 20.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -20.18 | -15.49 | -33.13 | -14.70 | -8.08 | -0.27 |
| Net Income | -21.31 | -15.53 | -33.42 | -14.59 | -9.03 | -0.32 |
| Shares Outstanding | 5.22 | 4.25 | 0.41 | 0.23 | 0.12 | 0.06 |
| Earnings Per Share | -4.08 | -3.65 | -80.75 | -64.25 | -113.50 | -5.25 |
| Operating Cash Flow | -7.04 | -14.45 | -26.90 | -11.04 | -5.43 | -0.20 |
| Capital Expenditures | -0.21 | - | - | - | - | - |
| Free Cash Flow | -7.25 | -14.45 | -26.90 | -11.04 | -5.43 | -0.20 |
| Cash & Equivalents | 13.92 | 2.85 | 18.48 | 24.04 | 3.62 | 0.00 |
| Total Debt | 0.12 | 0.14 | 10.04 | - | 6.42 | - |
| Net Cash / Debt | 13.81 | 2.70 | 8.44 | 24.04 | -2.80 | 0.00 |
| Assets | 14.47 | 3.82 | 19.02 | 24.75 | 4.49 | - |
| Liabilities | 2.18 | 0.36 | 15.08 | 4.12 | 8.92 | - |
| Book Value | 12.29 | -13.29 | 3.94 | 20.63 | -12.38 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NeuroBo Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Jeong Gu Kang |
Stock Information
| Ticker Symbol |
NRBO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NRBO |
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.